You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Aberration-correcting Topologically Optimized Metasurface (ATOM)
SBC: PHYSICAL SCIENCES INC. Topic: HR001119S003524Metalenses, with their ability to arbitrarily control the amplitude and phase of light across a band of wavelengths, have the potential to disrupt imaging and communication systems which rely on traditional lenses to focus, collimate, and otherwise manipulate optical signals, and are under increasing pressure to operate with reduced size and weight. We propose to design, develop, and demonstrate a ...
STTR Phase I 2020 Department of DefenseDefense Advanced Research Projects Agency -
AFARI: A Stylized Adaptive Mobility and Fitness Device for Outdoor Movement
SBC: R M BEAUMONT CORP Topic: NIADESCRIPTION provided by applicant Osteoarthritis OA diagnosed in over of the US population is the primary cause of musculoskeletal lower extremity disability Although there is no cure exercise remains the core treatment to manage OA regardless of age comorbidity pain severity or disability Yet many people with this condition do not engage in regular fitness and thus may resort t ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A Genes-to-Molecules Platform for Expanding Natural Product Diversity
SBC: Lassogen, Inc. Topic: NCCIHProject Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A high-throughput kit for detection of RNA modifications
SBC: MAVERIX BIOMICS, INC. Topic: NIDADESCRIPTION provided by applicant The broad objective of this project is to develop an integrated wet lab dry lab kit for high throughput detection of RNA modifications The final product will provide all required molecular biology reagents a set of simple and robust experimental manipulations for facile analysis of modifications and researcher friendly analytic cloud based software requi ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A hormonal therapy for preeclampsia
SBC: ADEPTHERA, LLC Topic: NICHDDESCRIPTION provided by applicant Preeclampsia is a pregnancy specific hypertensive disorder that can lead to multi organ failure seizure and maternal death Preeclampsia is also responsible for as many as of premature births in the United States Although better neonatal care has improved the likelihood of preterm babies surviving many face increased mortality and serious long term mor ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulation
SBC: REBISCAN, Inc. Topic: NProject Summary/Abstract !Amblyopia is vision loss caused by neglect of a structurally normal eye due to strabismus, asymmetric refraction (anisometropia), or deprivation. It is irreversible if not treated by age 7, but half of all patients in the U.S. are undetected and untreated until after it is too late, making it the leading cause of preventable vision loss. Rebion (Rebiscan, Inc) has develop ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A new treatment for NSAID-associated gastrointestinal damage
SBC: Anteana Therapeutics Inc Topic: NIDDKDESCRIPTION provided by applicant Non steroidal anti inflammatory drugs NSAIDs are among the most widely consumed pharmaceuticals but their prolonged use causes gastric injury and damage to the small intestine Previous work has shown that anandamide an endogenous endocannabinoid substance produced in the gastrointestinal GI mucosa plays an important role in epithelial homeostasis and re ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A novel device for cervical insufficiency in pregnant women
SBC: Cx Therapeutics, Inc Topic: NICHDAbstract In normal pregnancy, the cervix remains closed until term and then dilates under the influence of uterine contractions. In cases of cervical insufficiency (CI), the cervix dilates in the second trimester in the absence of uterine contractions, which leads to a preterm birth. Infants born prematurely are at risk of lifelong morbidities including chronic lung disease, feeding difficulties, ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A novel drug detection assay using fluorescent biosensor technology
SBC: GLSynthesis Inc. Topic: 300DESCRIPTION provided by applicant This phase project has as its overall objectives to design engineer optimize and implement a novel genetically encoded fluorescent drug sensor FDS based on F rster Resonance Energy Transfer FRET by exploiting conformational rearrangements induced by drug interactions with human serum albumin SA SA is uniquely suited for a general drug sensor beca ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A Novel, Field-Deployable, Biomimetic Narcotics Detector for the Identification of Fentanyl and Other Synthetic Opioids
SBC: SEACOAST SCIENCE, INC. Topic: NIDAAbstractThe alarming scope of the rapidly growing opioid epidemic has commanded the nation’s attention. The White House’s Council of Economic Advisers estimates that in 2015, the economic cost of the opioid crisis was over $504.0 billion (2.8% of GDP); and it is only expected to continue rising. Today, 1 in 5 fatalities amongst young adults is opioid related; with half a million fatal overdose ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health